Author | Randall Hurban


Late in the Game

Successful Product Manager's Handbook

If your medical affairs group is increasingly asking for more money to finance late-phase research, your company is not alone. Spending across all drug phases is currently growing at approximately 12 percent per year, and some analysts predict that Phase IIIb/IV investment may be the fastest-growing component of drug development. Why is there need for more money? Here are some reasons why late-phase investment is good for your brand.